Our Science – Ho Website
Mitchell Ho, Ph.D.
| Q&A With Mitchell Ho, Ph.D. - Dr. Ho is a recipient of Ovarian Cancer Research Fund's Individual Investigator Award.|
| The NIH Antibody Interest Group (ABIG) - Monthly ABIG serminar series are open to everyone interested.|
BIOC301/302 - Biochemistry I/II
- FAES Graduae School at the NIH.
BIOC 301 and 302 are a comprehensive survey of biochemistry at the graduate level.
| Understanding Mesothelioma By CURE Media Group - Q&A With Dr. Mitchell Ho, the recipient of the Mesothelioma Applied Research Foundation Craig Kozicki Memorial Grant|
| NCI/CCR: Novel Antibody Targets Glypican-3 in Liver Cancer - The Ho lab generated a new human single-domain antibody, HN3, that recognizes glypican-3 for liver cancer therapy. (NCI/CCR News. March 11, 2013)|
| Nature Reviews: The promise of new approaches in the management of hepatocellular carcinoma - "Mitchell Ho and colleagues investigated the potential of therapeutic antibodies for HCC." Nature Reviews Gastroenterology and Hepatology, Published online 26 March 2013|
| Nature SciBX: Glypican-3 (GPC3) - NCI patent application filed; available for licensing. Contact: Mitchell Ho, National Cancer Institute, Bethesda, MD. e-mail: email@example.com. SciBX 6(11); doi:10.1038/scibx.2013.262 Published online March 21 2013|
Dataset: Global Gene Expression Microarray for 2D and 3D Cultures of NCI-H226
- Gene expression microarray datasets from the NCI-H226 mesothelioma cell line: 2D and 3D cell cultures.
| Dr Mitchell Ho's talk at 2013 AACR Annual Meeting - Immune-based therapies targeting mesothelin and MUC16/CA125 (video and slides)|
| Breast Cancer Startup Challenge - The Challenge features inventions developed by scientists at NCI and Avon Foundation grantees to accelerate breast cancer therapy. The anti-mesothelin antibody technology developed in the Ho lab is one of ten inventions chosen for the Challenge.|
| Single-Domain Antibodies - Interview with Dr. Mitchell Ho, Genetic Engineering & Biotechnology News (Vol.33, No. 16; Sept 15, 2013)|
| Novel Antibody Targets Glypican-3 in Liver Cancer - CCR Connections (Volume 7, No. 1; 2013)|
| NCI's Introduction to Cancer Research Careers (ICRC) Program - Arelys Flores Vazquez, an ICRC Summer Intern in the Ho lab, presented at 2013 NIH Summer Poster Day.|
| NCI/CCR: Wnt Inactivation for Liver Cancer Therapy - The Ho lab demonstrates the development of a human monoclonal antibody targeting the heparan sulfate chains of glypican-3 involved in the Wnt signaling pathway, providing a potential cancer therapy. (NCI/CCR News. January, 2014)|
This page was last updated on 3/1/2014.